



SDI Review Form 1.6

Journal Name:	International Research Journal of Pure and Applied Chemistry
Manuscript Number:	2014_IRJPAC_13578
Title of the Manuscript:	Novel salts of Sunitinib an anticancer drug with improved solubility
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	Line no. 13-DI stands for----- (Not to used short forms in abstract) Line no. 19- Keyword should be conformer instead of maleate	Corrected Corrected
Minor REVISION comments	Line no. 54-Solubility is 25mg/ml? (try to correlate with BCS classification system) Whether it is BCS class II or Class IV drug. Target site of absorption is from stomach/intestine. Whether this drug molecule is official in IP,BP,USP, NF. Detail description must be needed about objectives of this article with novelty. Line no. 98- Solubility data needs to be explain in detail.	Clarified Specified, it is class III drug. Primary Reference Standard for sunitinib is not listed in United States Pharmacopoeia. But is a FDA approved drug. We are preparing API i.e. sunitinib in terms of quality and efficacy w.r.t. innovator drug (Sutent from Pfizer).
Optional/General comments	Need to study preformulation of selected conformers and drug with respect to bulk density, flow property, compressibility, carrs index. Need to check the solubility of marketed formulation. Need to go for optimization by factorial design. Represent the data in very well manner so that readers Should get the information and try to correlate with main findings. competing interest:-If there are any competing interest please clarify	This is very preliminary data as these are the novel salts and the few salts have improved water solubility over innovator salt (Malate) and these are the pharmaceutically acceptable salts so further studies will be carried out after standardization of API. (Solubility of Marketed form incorporated in paper and highlighted in yellow colour) Corrected